PEG: Loss narrowed, clinical milestones advanced, and 2026 guidance targets first revenue
Okuma süresi: 1 dakikadan kısa
Net loss narrowed significantly in 2025 due to lower R&D spend and cost discipline. Clinical progress included regulatory approval for RNX-011 Phase 2 and advanced partner talks for RNX-051. 2026 guidance anticipates first revenues and continued clinical milestones.
Original document: Pharma Equity Group A/S Class A [PEG] Slides Release — Mar. 25 2026
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
© AI-generated summary is provided by Quartr